AXL and Alzheimer disease: Immuneregulatory AXL-expressing monocytes expanded along with the progression of cirrhosis, representing <5% in early stages and up to 40% of monocytes in later stages, but were scarce following an event triggering AD (<5%) (Brenig et al., 2020).